Phenylalanine and Tyrosine Kinetics in Critically Ill Children with Sepsis

LEITICIA CASTILLO, Y. MING YU, J. SERGIO MARCHINI, THOMAS E. CHAPMAN, MELCHOR SANCHEZ, VERNON R. YOUNG, AND JOHN F. BURKE

Laboratory of Human Nutrition, Clinical Research Center and School of Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 [L.C., Y.M.Y., T.E.C., M.S., V.R.Y.]; Shriners Burns Institute, Boston, Massachusetts 02114 [L.C., Y.M.Y., T.E.C., V.R.Y.]; Pediatric and Neonatal Intensive Care Units, Children's Service, Massachusetts General Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02114 [L.C., M.S.]; Division of Nutrition-School of Medicine, Ribeirao Preto, SP 14049-900, Brazil [J.S.M.]; and Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114 [J.F.B.]

ABSTRACT. To better understand the impact of severe illness on the amino acid economy and nutritional needs of pediatric patients, we studied plasma phenylalanine and tyrosine kinetics in eleven critically ill patients (six full-term newborns and five young infants). Within 48 h of the diagnosis of sepsis they were given primed constant i.v. infusions of L-[1-13C]phenylalanine and L-[3,4,3H]tyrosine for 4 h. Routine nutritional support continued during this period by parenteral administration of dextrose, lipid emulsion, and an amino acid mixture low in tyrosine. Phenylalanine and tyrosine fluxes and rate of phenylalanine hydroxylation did not differ significantly between the two age groups, and so the data were combined for evaluation. For the entire group, values (μmol·kg⁻¹·h⁻¹; mean ± SD) for phenylalanine and tyrosine fluxes and rate of phenylalanine hydroxylation were 132 ± 24, 66 ± 16, and 29 ± 12, respectively. Plasma phenylalanine to tyrosine concentration ratio was 1.67 ± 0.6. From a comparison of the rate of phenylalanine hydroxylation with measured phenylalanine intakes, it was concluded that their routine, clinical nutritional support was inadequate to achieve body phenylalanine balance. In comparison with published data, the relative rate of phenylalanine hydroxylation appears to be high. We speculate that tyrosine is a conditionally dispensable amino acid under these conditions; it would be desirable to establish the intake levels and ratio of phenylalanine to tyrosine that effectively support aromatic amino acid balance in these critically ill patients. (Pediatr Res 35: 580–588, 1994)

Adequate nutritional support of critically ill patients represents an essential component of medical care (1, 2), with well-nourished patients having better outcome and a shorter hospital stay (3, 4). Although current nutritional regimens provided to critically ill children are based largely on the nutritional requirements for healthy children (5, 6), these patients are often hypermetabolic and show profound changes in the pattern of energy substrate and amino acid use. It is likely that more effective nutritional therapies will evolve after a better understanding of the quantitative changes in nutrient metabolism, and the mechanisms responsible for them, under these disease conditions.

In this study we examined plasma kinetics of phenylalanine and tyrosine metabolism in critically ill neonates and infants with sepsis. These amino acids are substrates for protein synthesis and precursors of physiologically important metabolites, such as catecholamines and thyroid hormones. We hypothesized that the standard parenteral nutritional support given during the acute stage of critical illness to our patients might be insufficient to meet the aromatic amino acid requirement of these patients and that tyrosine, usually considered to be a nutritionally dispensable amino acid, becomes “conditionally” indispensable during hypermetabolic states. Therefore, an adequate exogenous supply of tyrosine would be necessary to support fully and effectively the nutritional needs of the patient. To explore these hypotheses, we investigated plasma phenylalanine and tyrosine fluxes in 11 critically ill newborns and young infants with [13C]phenylalanine, [14C]tyrosine, and [3H]tyrosine as labeled tracers. Our findings are compared with published data derived in healthy newborns using similar tracer protocols (7).

MATERIALS AND METHODS

Patients. Eleven critically ill patients (six full-term newborns and five young infants) were studied. Their clinical characteristics are described in Table 1. All the newborns had appropriate weight for gestational age. The body weights of the five infants were below the 5th percentile for age (8). All patients had a diagnosis of sepsis and were admitted to the Neonatal and Pediatric Intensive Care Units at the Massachusetts General Hospital. Patients were studied within 48 h of the diagnosis of sepsis once hemodynamic stability was achieved. Sepsis in newborns was defined by the presence of two or more of the following: history of maternal fever or chorioamnionitis, rupture of membranes greater than 18 h, signs of respiratory distress, temperature instability, changes in level of consciousness or lethargy, shock, with a blood cell count greater than 20 000 cells/mm³ or less than 5000 cells/mm³, a left shift with more than 10% band forms or greater than 60% polymorphonuclear forms, or a positive blood culture or evidence of clinical sepsis syndrome (9). Sepsis in infants was defined as bacteremic if there was a positive blood culture, or it was defined as clinical sepsis syndrome if three or more of the following were found: clinical evidence of infection (pneumonia, meningitis, for example), fever or hypothermia, tachypnea, tachycardia, or symptoms of decreased organ perfusion such as oliguria, lethargy, or increased lactate level (10).

In the newborn group of six patients, three of them had positive blood cultures at diagnosis. Patient 2 had a positive blood culture...
to group B streptococci, patient 3 had a positive peripheral blood culture to *Staphylococcus epidermidis*, as well as positive blood culture to the same organism obtained from the central line placed for cardiac surgery. Patient 4 had a positive blood culture to *Escherichia coli* and positive culture to *Clostridium perfringens*, *Haeomophilus parainfluenza*, and *E. coli* from peritoneal fluid obtained during colectomy and ileostomy for necrotizing enterocolitis. Patient 5 came to the emergency department with shock, seizures, thrombocytopenia, leukopenia, and metabolic acidosis. Viral and bacterial cultures remained negative, and a workup for sepsis syndrome was done. All patients had variable degrees of metabolic acidosis and respiratory distress syndrome and multiorgan failure developed in patients 4 and 5.

Leukopenia was present in patients 2 and 6, or three (dopamine, dobutamine, and epinephrine in patients 1, 3, and 5), two (dopamine and dobutamine in patients 2 and 6), or three (dopamine, dobutamine, and epinephrine in patient 4) inotropic agents. All patients required inotropic support and had arterial and central venous lines in place. The newborn patients required a servocontrol radiant warmer to maintain skin temperature at 36.5°C. Infants were studied in a room with ambient temperature of about 25°C and relative humidity of 40%.

Physiologic Stability Index (11), Neonatal Physiologic Stability Index (12), and Therapeutic Intervention Score System (13) scores were obtained in each patient. These three systems objectively assess severity of disease and predict outcome (chances of death or survival). The Physiologic Stability Index and Neonatal Physiologic Stability Index estimate the degree of derangement in seven major physiologic systems (cardiovascular, respiratory, neurologic, hematologic, renal, gastrointestinal, and metabolic). After the degree of abnormality is assessed, each variable is assigned a score of 1, 3, or 5, indicating the clinical importance of the derangement. A score of 3 in a given variable mandates a change in therapy; a score of 5 indicates a life-threatening situation. The Therapeutic Intervention Score System evaluates the degree of intervention that a patient requires. Therapeutic interventions are classified from 1 to 4. Score 1 indicates routine care interventions (ECG monitoring, supplemental oxygen, i.v. antibiotics, for example); score 2 indicates more invasive therapeutic or monitoring interventions, such as central venous pressure line and more than two i.v. lines or hemodialysis; score 3 indicates invasive therapeutic or monitoring interventions that may be lifesaving, such as endotracheal intubation. Score 4 indicates interventions in response to major events, such as cardiopulmonary resuscitation, pulmonary artery catheter placement, and cardiac pacing. These scores are routinely used in intensive care units for assessing severity of illness, with higher scores indicating a greater severity of the disease.
Study protocol. The study protocol was approved by the Subcommittee on Human Studies at the Massachusetts General Hospital. Written informed consent was obtained from the patient’s parents or guardians. We used the arterial line as the sampling source and the central venous line for tracer infusion. Isotope tracers were infused by means of a calibrated syringe pump (Harvard Apparatus, Natick, MA). Verification of isotopic purity was obtained before the infusion study. Both tracer solutions (see below) were infused at a rate of 4.7 mL·h⁻¹ except for infants 9 and 10, who received an infusion rate of 10.74 mL·h⁻¹ because of their higher body weight. All patients received priming tracer doses of 5.4 μmol·kg⁻¹·h⁻¹ of [1-¹³C]phenylalanine (99 atoms percent), and 3.6 μmol·kg⁻¹·h⁻¹ of l-[3,3-²H₂]tyrosine (98 atoms percent). The [¹³C]phenylalanine-derived tyrosine pool was primed with 2.5 μmol·kg⁻¹·h⁻¹ of l-[3,3-²H₂]tyrosine (98 atoms percent). Tracers were purchased from Tracer Technologies, Inc. (Somerville, MA). These primes were followed by 4-h constant i.v. infusions with [¹³C]phenylalanine and [²H₃]tyrosine at rates of 4.1 and 3.0 μmol·kg⁻¹·h⁻¹, respectively. Labeled tracers were confirmed to be sterile and pyrogen free before use.

Blood samples for determinations of plasma phenylalanine and tyrosine isotopic enrichment and free plasma amino acid concentrations were obtained at 0, 180, 200, 210, and 240 min in all patients. The samples were placed in tubes containing heparin and centrifuged immediately, and the plasma was stored at -80°C until used for analysis. The total amount of blood withdrawn during the entire study period in each patient was less than 5 mL.

Nutritional support. Nutritional support could not be manipulated experimentally in this investigation and so was provided as indicated by the routine clinical care of these critically ill infants. Hence, the levels of energy and protein intake varied as indicated by the routine clinical care of these critically ill infants. Hence, the levels of energy and protein intake varied between subjects. Mean energy intakes for neonates and infants were 35 and 40 kcal·kg⁻¹·d⁻¹ respectively, provided principally as a 10-20% dextrose solution and a soybean lipid emulsion containing both [¹³C] and [³H] tracers overlap, estimation of sample enrichments was based on multiple linear regression, where the various mass spectrometer signals were used as dependent variables and the sample enrichments served as unknown parameters. The coefficients of the regression equations were derived from standard mixtures ranging from 0 to 8% mole fraction for [¹³C]phenylalanine and [³H]tyrosine and 0 to 6% mole fraction for [¹³C] tyrosine. A further set of five standard mixtures was also prepared containing both [¹³C] and [³H] tyrosine. Each sample was measured in duplicate and multiple samples measured during the isotopic plateau. Additional details concerning the determination of plasma isotopic enrichments of phenylalanine and tyrosine are given in the appendix.

The rate of phenylalanine conversion to tyrosine (QPdT; pmol·kg⁻¹·h⁻¹) was calculated by isotope dilution, as previously described for leucine (19):

$$Q = \frac{i \cdot (E_i - 1)}{E_p}$$

where i is the rate of tracer infusion (μmol·kg⁻¹·h⁻¹) and Ei and Ep are the isotopic enrichments of the infusion and plasma amino acid, respectively.

The rate of phenylalanine conversion to tyrosine (QPEDIUM; μmol·kg⁻¹·h⁻¹) (phenylalanine hydroxylation) was derived as follows:

| Amino acid | Unit of measure | Nitrogen (g/L) |
|------------|----------------|---------------|
| Isoleucine | g/L            | 6.09          |
| Leucine    | g/L            | 8.44          |
| Lysine     | g/L            | 11.50         |
| Methionine | g/L            | 5.35          |
| Phenylalanine | g/L       | 6.70          |
| Threonine  | g/L            | 6.70          |
| Tryptophan | g/L            | 2.61          |
| Valine     | g/L            | 8.73          |
| Alanine    | g/L            | 25.94         |
| Arginine   | g/L            | 24.57         |
| Histidine  | g/L            | 18.41         |
| Proline    | g/L            | 8.28          |
| Serine     | g/L            | 6.00          |
| Glycine    | g/L            | 14.74         |
| Tyrosine   | g/L            | 0.23          |
| Glutamic acid | g/L    | 5.43          |
| Aspartic acid | g/L     | 3.47          |
| Total      |                | 168.39        |

* Novamine 11.4% (composition data provided by Clintec, Deerfield, IL).
where QT and QP are the tyrosine and phenylalanine fluxes, respectively, estimated from the primed constant infusions of [1-13C]tyrosine and 1-13Cphenylalanine; Ep and Et are the plasma enrichments of 1-13Ctyrosine and 1-13Cphenylalanine, respectively; ip is the rate of infusion of the labeled phenylalanine. As discussed by Thompson et al. (18), the term Qp/(ip + Qp) corrects for the contribution of the phenylalanine tracer infusion to QT.

The rate of phenylalanine disappearance by incorporation into proteins (Phes) was estimated by subtracting the rate of phenylalanine hydroxylation (Qp-τ) from phenylalanine flux (Qp):

\[ \text{Phes} = Q_p - Q_{p-\tau} \tag{3} \]

Phenylalanine entering the plasma pool by protein breakdown (Phbn) was determined from phenylalanine flux and phenylalanine intake (pi):

\[ \text{Phbn} = Q_p - \pi \tag{4} \]

Thus, from equations 3 and 4, the body balance of phenylalanine (PhesAL) can be obtained:

\[ \text{PhesAL} = \text{Phes} - \text{Phbn} \tag{5} \]

The rates of whole body protein synthesis and breakdown were obtained according to Thompson et al. (18) assuming the phenylalanine content of whole body mixed proteins to be 280 μmol/g protein. We have expressed these rates as g·kg⁻¹·d⁻¹. Thus:

\[ \text{ProtS} = \frac{\text{Phes} \times 24}{280} \tag{6} \]

\[ \text{ProtB} = \frac{\text{Phes} \times 24}{280} \tag{7} \]

and

\[ \text{ProtSAL} = \text{ProtS} - \text{ProtB} \tag{8} \]

**Data analysis.** Results are summarized as means ± SD as a measure of dispersion of the individual data points. Primary and derived values were tested for significance between infant and newborn groups using analysis of covariance with age, weight, and severity of disease as variables. Adjusted means were tested for significance with a least-squares mean procedure. Dependent variables included phenylalanine flux (Qp), tyrosine flux (Qt), phenylalanine hydroxylation (Qp-τ), and protein turnover (ProtS, ProtB, and ProtSAL). Because no statistically significant differences were observed between newborns and infants, the results for both groups were combined for purposes of comparing these values with those reported in the literature (7). A p < 0.05 was chosen as being statistically significant. Relationships among variables were tested for significance using Pearson’s product moment correlation. The relationship between phenylalanine and tyrosine intake with phenylalanine and protein balance was evaluated by least-squares linear regression analysis. An SAS program (Cary, NC) was used for the statistical analysis (20).

**RESULTS**

Energy and protein intakes for the patients during the period of study are shown in Table 3. The levels of intake were lower than those recommended for healthy newborns and infants (21), which generally reflects our patients’ critical clinical status. Critically ill patients often require infusion of multiple drugs, blood products, and fluids at the expense of their nutritional support. Furthermore, fat administration in the presence of respiratory failure or sepsis is often restricted by attending physicians because of concerns about possible lipid-induced impairment of respiratory and immune function (22-24).

The Plasma-free phenylalanine and tyrosine concentrations during the tracer study period are shown in Table 4. The phenylalanine/tyrosine ratio in these patients with sepsis was increased (1.67) when compared with values reported for healthy newborns (0.71) (25) and adults (0.82) (26, 27).

A steady state level of isotopic enrichment in plasma of our patients was achieved during the 4-h continuous tracer infusion period as determined by lack of a statistically significant slope in the plasma pools of phenylalanine and tyrosine isotopologs (Fig. 1). For the entire group of patients, the mean coefficients of variation for plasma isotope enrichment plateaus were 7, 5, and 11% for 13Cphenylalanine, [13C]tyrosine, and [14N]tyrosine, respectively. Their kinetics and the rates of whole body protein turnover were calculated from these isotopic enrichments of plasma phenylalanine and tyrosine.

Phenylalanine and tyrosine fluxes and rates of phenylalanine hydroxylation were 137 ± 17, 63 ± 13, and 34 ± 6 μmol·kg⁻¹·h⁻¹ in the neonates and 126 ± 29, 70 ± 18, and 24 ± 14 μmol·kg⁻¹·h⁻¹ in the infants (Table 5). Considerable variation existed within each group, and differences between group means were statistically significant for phenylalanine (p < 0.1). Therefore, for our purposes, we considered it appropriate to combine the results into one data set for the further comparisons given below. The combined group mean phenylalanine flux was 132 μmol·kg⁻¹·h⁻¹, with a mean phenylalanine hydroxylation rate of 29 μmol·kg⁻¹·h⁻¹, representing 22% of the phenylalanine flux.

The components of phenylalanine flux are presented in Table 6. Tyrosine intakes were very low (mean, 0.6 μmol·kg⁻¹·h⁻¹). Intakes of phenylalanine ranged widely, with the mean being 17.4 μmol·kg⁻¹·h⁻¹. Extrapolated to a daily basis, this amounts to a mean intake of 69 mg·kg⁻¹·d⁻¹, which is in the requirement range for healthy infants when tyrosine intakes are generous (28), but it presumably would be less than adequate (21) for tyrosine intakes that are low, as in the present study. Also, because the mean phenylalanine hydroxylation rate was 29 μmol·kg⁻¹·h⁻¹ (equivalent to 115 mg·kg⁻¹·d⁻¹) (Table 5), the group of patients as a whole were in negative body phenylalanine balance. In Table 6, we summarized the rates of disappearance of phenylalanine from plasma by protein synthesis (Phes) and entry into plasma by protein degradation (Phbn). Again, these rates reflect the extent of the negative body phenylalanine balance, which was a mean of −14 μmol·kg⁻¹·h⁻¹ for the combined groups.

The derived values for body protein turnover are presented in Table 7. Mean protein synthesis and breakdown rates were 8.6 and 9.8 g protein·kg⁻¹·d⁻¹, respectively, for the combined two study populations.

The following statistical correlations were observed in these children with sepsis: body protein balance was negatively correlated (R² = 0.5; p < 0.01) with the rate of phenylalanine hydroxylation to tyrosine and positively correlated (R² = 0.4, p < 0.04) with phenylalanine intake (Fig. 2).

**DISCUSSION**

We have investigated the kinetics of whole body phenylalanine and tyrosine metabolism in critically ill children with sepsis. Despite the importance of phenylalanine as an indispensable amino acid and as precursor for tyrosine, relatively few studies address phenylalanine and tyrosine kinetics in relationship to the metabolic needs and nutritional status of pediatric patients (29-31). To our knowledge, no similar studies appear to have been conducted previously in critically ill children with sepsis. Because we were not able to investigate a healthy cohort, our combined data for phenylalanine and tyrosine kinetics, as well as the estimates obtained for whole body protein turnover in critically ill young infants with sepsis are compared here with those of Denne et al. (7), who have reported similar data for seven normal, term infants studied at approximately 21 d of age. In their study, phenylalanine and tyrosine fluxes and rates of phenylalanine hydroxylation were 76 ± 12, 53 ± 12, and 12 ± 3, respectively,
Table 3. Energy and macronutrient intakes by parenteral feeding in critically ill newborns and infants

| Patient and group | Glucose (mg·kg⁻¹·min⁻¹) | Protein (g·kg⁻¹·d⁻¹) | Lipid (g·kg⁻¹·d⁻¹) | Energy (kcal·kg⁻¹·d⁻¹) |
|------------------|--------------------------|----------------------|---------------------|------------------------|
| Newborns         |                          |                      |                     |                        |
| 1                | 6.9                      | 1.3                  | 0                   | 32.8                   |
| 2                | 5.8                      | 1.5                  | 0                   | 29.2                   |
| 3                | 6.5                      | 1.0                  | 1.0                 | 32.4                   |
| 4                | 3.0                      | 0                   | 2.0                 | 26.0                   |
| 5                | 13.0                     | 2.4                 | 1.0                 | 61.6                   |
| 6                | 5.0                      | 1.0                  | 1.0                 | 30.3                   |
| Mean ± SD        | 6.7 ± 3                   | 1.2 ± 0.7            | 0.5 ± 0.7           | 35 ± 11.9              |
| Infants          |                          |                      |                     |                        |
| 7                | 6.1                      | 1.0                  | 1.0                 | 30.5                   |
| 8                | 6.0                      | 1.0                  | 1.0                 | 29.9                   |
| 9                | 6.0                      | 0                   | 0.5                 | 24.0                   |
| 10               | 14.9                     | 2.6                 | 0.5                 | 70.9                   |
| 11               | 8.9                      | 1.6                 | 1.0                 | 44.0                   |
| Mean ± SD        | 8.4 ± 3.5                 | 1.2 ± 0.8            | 0.7 ± 0.4           | 39.9 ± 16.8            |

Table 4. Plasma-free phenylalanine and tyrosine concentrations in newborns and infants with sepsis

| Phenylalanine (μmol/L) | Tyrosine (μmol/L) |
|------------------------|-------------------|
| Neonates               |                   |
| 1                       | 55.1              | 30.7            |
| 2                       | 125.3             | 68.8            |
| 3                       | 163.8             | 109.2           |
| 4                       | 149.4             | 61.5            |
| 5                       | 69.0              | 55.5            |
| 6                       | 134.7             | 106.9           |
| Mean ± SD              | 116 ± 44          | 72 ± 31         |
| Phenylalanine/tyrosine  | 1.6 ± 0.05        |
| ratio                  |                   |
| Infants                |                   |
| 7                       | 66.7              | 49.0            |
| 8                       | 64.4              | 41.0            |
| 9                       | 74.3              | 35.2            |
| 10                      | 77.3              | 52.7            |
| 11                      | 79.6              | 23.2            |
| Mean ± SD              | 72.5 ± 7          | 40.2 ± 12       |
| Phenylalanine/tyrosine  | 1.8 ± 0.9         |
| ratio                  |                   |
| Combined data          | 96 ± 37           | 58 ± 26         |
| Phenylalanine/tyrosine  | 1.7 ± 0.6         |
| ratio                  |                   |

for the fasted state and 86 ± 13, 46 ± 8, and 10 ± 3 (mean ± SD; μmol·kg⁻¹·h⁻¹), respectively, for the fed state. These investigators used [²H₃]phenylalanine and [²H₂]tyrosine as tracers. Thus, phenylalanine fluxes are higher in our patients with sepsis when compared with the healthy newborns, as might be anticipated for a hypermetabolic, catabolic condition. When the intravenously administered phenylalanine intake is subtracted from phenylalanine flux, the "corrected," mean phenylalanine flux is 115 ± 24 μmol·kg⁻¹·h⁻¹, remaining higher than that in healthy newborns (7). This correction for i.v. intake of phenylalanine is necessary, particularly because Wykes et al. (31) found that phenylalanine flux was greatly affected by the parental phenylalanine supplied. Tyrosine fluxes in our group of critically ill infants with sepsis were similar or perhaps somewhat higher than those in healthy neonates (7), who were also receiving no tyrosine by i.v. feeding. Also, the hydroxylation of phenylalanine, expressed either as an absolute rate or as a percentage of the phenylalanine flux, was higher in our patients than was phenylalanine hydroxylation in newborn infants as reported by Denne et al. (7). Some difficulty exists, however, in drawing a strict comparison between the present hydroxylation data and those of Denne et al. (7) because pentadeteriated phenylalanine was used as tracer by these latter investigators; we have shown recently in healthy adults that this tracer underestimates hydroxylation rates in vivo by about a factor of 2.0 (32). For this reason, the estimate of 10–12 μmol·kg⁻¹·h⁻¹ for phenylalanine hydroxylation in healthy newborns (7) might be lower than the actual rates, although that is speculative and a matter for further study.

The values for Prote and Prote in our patients with sepsis are somewhat higher than the 7 and 6 g·kg⁻¹·d⁻¹, respectively, reported for healthy infants (25, 33), although perhaps they are not as high as might be anticipated for hypermetabolic or acute catabolic states (34).

Despite these difficulties, in fully comparing the present values with those appearing in the published literature, the present data point to changes in kinetics and in the relationship between phenylalanine and tyrosine metabolism in infants with sepsis versus normal infants. For example, phenylalanine fluxes in our critically ill infants are considerably higher than those reported for normal babies (7). Furthermore, the flux ratio of phenylalanine to tyrosine was higher in our infants than in the normally growing newborns studied by Denne et al. (7). This finding is consistent with previous reports (35) showing an increased plasma phenylalanine/tyrosine concentration ratio in patients with sepsis.
with sepsis, suggesting an increased rate of muscle breakdown, reduced rate of incorporation of phenylalanine into muscle proteins, and/or an alteration in the rate of hepatic conversion of phenylalanine to tyrosine (26, 27, 35, 36). Also, during protein deficiency, phenylalanine use decreases, leading to a relative increase in the plasma phenylalanine level, which again is possibly due to a decreased enzymatic conversion of phenylalanine to tyrosine (37, 38). Of course, the low content of tyrosine in the parenteral amino acid mixture would also be expected to raise the plasma-free phenylalanine/tyrosine ratio, although the ratio was also high in the two patients (patients 4 and 9) who were receiving glucose alone. This finding suggests an altered aromatic amino acid homeostasis in our patients and possibly a change in the coupling between phenylalanine kinetics, hydroxylation, and tyrosine homeostasis and oxidation. We speculate that because of the stressful or catabolic state combined with the low tyrosine intake, an impaired balance exists among phenylalanine retention, hydroxylation, and tyrosine homeostasis in these patients with sepsis. Thus, phenylalanine hydroxylation rates may be adaptively increased in these patients but with the net effects of impairing phenylalanine balance and inadequately meeting the metabolic needs for tyrosine. It is not unusual for critically ill patients with sepsis to develop supranormal values of physiologic parameters such as cardiac output or oxygen delivery that are still insufficient to meet their needs (39). We speculate that a similar situation may occur at the metabolic level, whereby multiple factors, such as increased protein breakdown and changes in the pattern of amino acid utilization and requirements, lead to increased rates of phenylalanine hydroxylation that are still insufficient to meet the tyrosine requirements. This hypothesis will need to be verified in follow-up investigations in which different intakes and ratios of phenylalanine and tyrosine intake are examined for their effects on phenylalanine and tyrosine kinetics. Alternatively, the altered rates of phenylalanine hydroxylation and their relationships to phenylalanine kinetics and intake might be a more general reflection of an impairment and changes in amino acid catabolism, which frequently occurs in sick and stressed patients (40, 41).

The clinically determined standard amount of total parenteral nutrition formulation routinely used in our critically ill patients...
appears to be inadequate to support their aromatic amino acid needs. From the data shown in Table 6, intakes in the range of about 30–40 μmol·kg⁻¹·h⁻¹ permit neutral body phenylalanine balances, suggesting that this intake level (equivalent to about 138 mg phenylalanine·kg⁻¹·d⁻¹) is probably an appropriate target for critically ill patients during the acute stage of their disease and in the virtual absence of a tyrosine intake.

Critically ill newborns and infants with sepsis who receive limited parenteral protein and energy intakes, as dictated by routine clinical practice (34, 42), are unable to maintain phenylalanine homeostasis, and because of the link between phenylalanine and tyrosine metabolism, it is to be expected that a deterioration in tyrosine homeostasis will occur. Indeed, tyrosine may become a "conditionally" indispensable amino acid under these circumstances despite an apparently generous supply of phenylalanine. The reason for this is that the formation of tyrosine from phenylalanine occurs principally in the liver, where this tyrosine may or may not be made as easily available in times of metabolic stress as an exogenous source of tyrosine would be for meeting the tyrosine needs of the body organs and tissues. Because of its poor solubility, most parenteral amino acid mixtures contain only a trace of tyrosine, while being designed to provide a generous phenylalanine intake; the assumption here is that the supply of phenylalanine will be sufficient to maintain an adequate availability of tyrosine where it is required. This assumption may be, and probably is, an overly simplistic assessment of phenylalanine-tyrosine interrelationships, particularly if the regulation of tissue and organ pools of phenylalanine and tyrosine occurs by way of separate systems and mechanisms and if these are, in turn, affected differentially by stress, including infection. Although another commonly used mixture (Trophamine, Kendall-McGaw Laboratories, Irvine, CA), has been supplemented with acetyl-tyrosine, the target intake level has been designed to support plasma amino acids concentrations similar to those observed in healthy full-term, breast-fed, 1-mo-old infants (43, 44). Although a possibly useful criterion, it is important to assess whether "normal" serum values represent an appropriate nutritional goal for the critically ill patients (45, 46). Current estimates of amino acid requirements in human subjects are based largely on nitrogen balance studies (21); in the case of children, these values are supplemented with data from measurements of growth rates in response to specific nutritional treatments (21, 47). In the case of critically ill neonates and infants, these procedures are not feasible, and we suggest, from the present experience, that application of stable isotope tracer methods might be a useful way to investigate the quantitative requirements for specific amino acids in these patients. Indeed, ¹³C-enriched amino acid tracers have been used successfully in adults to estimate minimum intakes required to achieve body balance of the irreversible oxidative losses of nutritionally indispensable amino acids (48). However, we recognize that for critically ill children with mechanically ventilated lungs it might be difficult to obtain accurate measurements of total ¹³C-labeled CO₂ and CO₂ production by indirect calorimetry, especially under conditions of the high air flow rates used to meet their ventilatory needs. Measurements of ¹³CO₂ in plasma is possible, but precise estimation of rates of total CO₂ production in these patients remains difficult. For these reasons, we chose to apply the present phenylalanine-tyrosine tracer model as described by Thompson et al. (18), except that we used [¹³C]phenylalanine instead of [²H₅-ring]phenylalanine as tracer, thereby obviating the need for breath collections and measurement of respiratory gas exchange rates.

In summary, we describe here, apparently for the first time, phenylalanine and tyrosine kinetics in critically ill pediatric patients with sepsis. From these observations we conclude that current clinical practice of total parenteral administration during critical illness is insufficient to meet the aromatic amino acid requirements of these patients. Under these circumstances, we also speculate that tyrosine may be a "conditionally" indispensable amino acid. Hence, consideration should now be given to defining adequate intakes of the aromatic acids and, in particular, the ratio between phenylalanine and tyrosine. We fully appreciate that the present study is limited by sample size, the variable clinical condition of our patients, lack of a concurrent control group of healthy infants, and the different, clinically determined intakes of macronutrients among the infants. Although these difficulties are commonly faced by investigators who are interested in carrying out precise metabolic studies in critically ill infants, we considered it important to begin to establish in quantitative terms whether the nutritional component of these infants' care was appropriate to the metabolic changes that accompany their disease state. Our findings indicate the desirability of now investigating the impact of the level of aromatic amino acid intake, including the exogenous supply of tyrosine when given in dipeptide form, on phenylalanine and tyrosine kinetics and balance and their functional significance in critically ill children with sepsis.
Acknowledgments. The authors thank Dr. J. David Todres and the nursing and respiratory care staff of the Pediatric and Neonatal Intensive Care Units for assistance in carrying out these demanding studies. We are indebted to Dr. Ronald Kleinman for his helpful comments and to Alice Traudt for her secretarial assistance.

REFERENCES

1. Cerra FB 1986 Nutrition in the critically ill: modern metabolic support in the intensive care unit. In: Chernow R, Shoemaker WC (eds) Critical Care State of the Art. Society of Critical Care Medicine, Annapol. CA, pp 1-17
2. Atakanzi J, Carpenter YA, Elnogi DH, Kinney JM 1980 Influence of total parenteral nutrition of fuel utilization in injury and sepsis. Ann Surg 191:40-46
3. Pollack MM, Wiley JS, Kastner R, Holbrook PR 1982 Malnutrition in critically ill infants and children. JPEN J Parenter Enteral Nutr 6:20-24
4. Pollack MM, Wiley JS, Holbrook PR 1981 Early nutritional depletion in critically ill children. Crit Care Med 9:560-563
5. Heid WC, Driscoll JM, Schullinger JM, Grebin B, Winters RW 1972 Intravenous alimentation in pediatric patients. J Pediatr 80:351-357
6. Holt JR, Le, Snyderman SE 1971 The amino acid requirements of children. In: Nyhan WL (ed) Amino Acid Metabolism and Genetic Variation. New York, McGraw-Hill, pp 381-390
7. Denne SC, Karm CA, Brondyke AD, Liu YM, Liechty EA 1993 Intravenous substrate increases whole protein synthesis and suppresses protein synthesis in normal growing newborns. Pediatr Res 33:302A (abstr)
8. National Center for Health Statistics 1976 NCHS growth charts. Monthly Vital Statistics Report, Vol 3, Suppl HRA
9. McCracken GH, Blisha JR 1987 Bacterial and viral infections of the newborn. In: Avery GB (ed) Neonatology. JB Lippincott, Philadelphia, pp 724-507
10. Bone RC 1991 Sepsis, the sepsis syndrome, multi-organ failure: a plea for heightened awareness. J Parenter Enteral Nutr 15:215-238
11. Conover R., Lorenzo A., Aran F., Garcia F. 1987 Significance of the changes in plasma amino-acid levels in meningococcal infection. Intensive Care Med 13:34-38
12. Freund HR, Atamian S., Holroyde J 1979 Plasma amino acids as predictors of the severity and outcome of sepsis. Ann Surg 190:571-574
13. Whitehead RG, Milburn TR 1964 Amino acid metabolism in kwashiorkor. Metabolism of phenylalanine and tyrosine. Clin Sci 26:279-289
14. Lucas A., Baker BA, Morley RM 1993 Hyperphenylalaninemia and outcome in intravenously fed preterm neonates. Arch Dis Child 68:579-583
15. Shoemaker WC, Kram HB, Appel PL 1990 Therapy of shock based on pathophysiology, monitoring, and outcome prediction. Crit Care Med 18:519-525
16. Wolfe RR, Jafoor H, Hartl WH 1989 Protein and amino acid metabolism after injury. Diabetes Metab Rev 5:149-164
17. Young 1990 validating two scoring systems which define nutritional risk in high risk surgical patients. Chest 97:934-938
18. Pitkanen M, Rutimann VE, Gesteon VT 1989 Validation of two scoring systems which define nutritional risk in high risk surgical patients. Chest 97:934-938
19. Pitkanen M, Rutimann VE, Gesteon VT 1989 Validation of two scoring systems which define nutritional risk in high risk surgical patients. Chest 97:934-938
20. Heid WC, Kashyap S 1992 Protein and amino acid requirements. In: Pollard R. Fox W (eds) Fetal and Neonatal Physiology. WB Saunders, Philadelphia, pp 450-462
21. Heid WC, Hay W., Helans R., Storm M., Kashyap S., Bell R. 1988 Pediatric parenteral amino acid mixture in low birth weight infants. Pediatrics 81:31-35
22. Shoemaker WC, Appel P., Kram H., Waxman K., Lee TS 1989 Prospective trial of super-normal values of survivors as therapeutic goals in high risk surgical patients. Chest 94:1176-1186
23. Rakeow EC, Astic ME, Weil MH 1992 Celluar oxygen metabolism during sepsis and shock: the relationship of oxygen consumption to oxygen delivery. JAMA 259:1989-1991
24. Ziegler EE, Fomon SJ 1982 Methods in infants nutrition research: balance and growth studies. Acta Paediatr Scand Suppl 299:90-96
25. Young VR, Bier DM, Pelfen PL 1989 A theoretical basis for increasing current estimates of the amino acid requirements in adult man, with experimental support. Am J Clin Nutr 50:80-92

APPENDIX

Calculations regarding [14C] and [2H3]tyrosine enrichments.

The isotopomers of tyrosine seen arising at m/z 466[M-57]+ in the electron impact mass spectrum of the tertiary butyldimethylsilyl derivative at the m/z 1 + (m/z 467) and m/z 2 (m/z 468) channels have abundances of 20% and 44%, respectively, relative to the main ion (m/z 466). The isotopomers of the trace therefore overlap with those of the less abundant [14C] and [2H3] tyrosine tracers present in the labeled plasma samples. If only one tracer was present in the samples to be analyzed, then standards containing mixtures of natural and [14C] or [2H3] tyrosine could be measured and a calibration graph constructed. The regression coefficient (slope) and y intercept (constant) could then be calculated by simple linear regression. These could be used to solve for the unknown enrichments in plasma. However, in these studies two tracers are present, and their isotopomers overlap. The [14C]-tracer that is found at m/z 467 has isotopomers arising from it that contribute to both the channel at m/z 468 where the [2H3]tyrosine is predominantly found. Also, the [2H3]tyrosine tracer has isotopomers arising from it at m/z 468 that are 10% of its signal and contribute to the channel at m/z 467 where the [14C]-tracer is predominantly found. If the contributions of these isotopomers are not taken into account, then an overestimate of both enrichments will be made, resulting in an underestimate of tyrosine flux and an overestimate of phenylalanine hydroxylation. For instance, in these studies the correct mean plasma [14C] and [2H3] tyrosine enrichments were about 1.5 and 5%, respectively. However, because of the 44% spill-up of the [14C]tyrosine tracer into the 2H3-tracer channel at m/z 468, the uncorrected enrichment would have been 5.7%. Also, because of the [2H3]tyrosine spill-down into the [14C]...
tyrosine channel at m/z 467, the uncorrected enrichment would have been 2.0%.

To accurately calculate the enrichment of both the [13C] and [1H2]tyrosine enrichments that allows the signals at both m/z 467 and m/z 468 to be taken into account, we carried out multiple linear regression of the ion ratios obtained from the standard mixtures as follows. First, the data obtained from the first set of standards containing only [13C]tyrosine and the second set of standards containing only [1H2]tyrosine were plotted by assigning the [13C] or [1H2]tyrosine mole fractions to the x axis and m/z 467/m/z 466 and m/z 468/m/z 466 to the y axis. These two calibrations were checked for linearity and outliers. Then the data obtained from the [13C] and [1H2]tyrosine mixtures were combined with the two sets of standards containing only one labeled tracer. Multiple linear regression was carried out by regressing mole fraction [13C]tyrosine against the ratios m/z 467/m/z 466 and m/z 468/m/z 466. The equation for [1H2]tyrosine mole fraction was then also obtained by regressing the mole fraction [1H2]tyrosine against the ratios m/z 467/m/z 466 and m/z 468/m/z 466. The following equations from the multiple regression least squares analysis were obtained:

\[ \text{Mole fraction } [13C]\text{tyrosine} = C'_0 + C'_1N_1 + C'_2N_2 \]

\[ \text{Mole fraction } [1H2]\text{tyrosine} = C''_0 + C''_1N_1 + C''_2N_2 \]

where \(C'_0\) and \(C''_0\) are the derived constants for the [13C] and [1H]tyrosine, respectively. \(C'_1\) and \(C''_1\) are the derived regression coefficients for [13C] and [1H]tyrosine at m/z 467/m/z 466, respectively. \(C'_2\) and \(C''_2\) are the derived regression coefficients for [13C] and [1H]tyrosine at m/z 468/m/z 466, respectively. These would then be used to calculate the mole fraction enrichments of the [13C] and [1H]tyrosine from the measured ratios (\(N_1\) and \(N_2\)) found in the plasma samples at m/z 467/m/z 466 and m/z 468/m/z 466, respectively.